TGA clears the way for a new hepatitis C treatment.

The Therapeutic Goods Administration (TGA) has recently approved the use of Sovaldi® (sofosbuvir) in Australia.  This is the first step in making this new treatment accessible to Australians living with chronic hepatitis C.  Hepatitis Australia welcomes the TGA listing of this transformative new treatment, which has very high cure rates combined with reduced side-effects.  We must now wait to see if the new treatment becomes available through the Pharmaceutical Benefits Scheme (PBS) to ensure its affordability to those who need it.